미국 CDC에서 나온 SARS의 전반적인 치료법에 대해 나온 리뷰를 한 번 볼까?

http://www.ncbi.nlm.nih.gov/pubmed/16968120

PLoS Med. 2006 Sep;3(9):e343.
SARS: systematic review of treatment effects.Author information
  • 1Centers for Disease Control and Prevention, Respiratory and Enteric Viruses Branch, Atlanta, Georgia, United States of America. lstockman@cdc.gov
Abstract
BACKGROUND:

The SARS outbreak of 2002-2003 presented clinicians with a new, life-threatening disease for which they had no experience in treating and no research on the effectiveness of treatment options. The World Health Organization (WHO) expert panel on SARS treatment requested a systematic review and comprehensive summary of treatments used for SARS-infected patients in order to guide future treatment and identify priorities for research.

METHODS AND FINDINGS:

In response to the WHO request we conducted a systematic review of the published literature on ribavirin, corticosteroids, lopinavir and ritonavir (LPV/r), type I interferon (IFN), intravenous immunoglobulin (IVIG), and SARS convalescent plasma from both in vitro studies and in SARS patients. We also searched for clinical trial evidence of treatment for acute respiratory distress syndrome. Sources of data were the literature databases MEDLINE, EMBASE, BIOSIS, and the Cochrane Central Register of Controlled Trials (CENTRAL) up to February 2005. Data from publications were extracted and evidence within studies was classified using predefined criteria. In total, 54 SARS treatment studies, 15 in vitro studies, and three acute respiratory distress syndrome studies met our inclusion criteria. Within in vitro studies, ribavirin, lopinavir, and type I IFN showed inhibition of SARS-CoV in tissue culture. In SARS-infected patient reports on ribavirin, 26 studies were classified as inconclusive, and four showed possible harm. Seven studies of convalescent plasma or IVIG, three of IFN type I, and two of LPV/r were inconclusive. In 29 studies of steroid use, 25 were inconclusive and four were classified as causing possible harm.

CONCLUSIONS:

Despite an extensive literature reporting on SARS treatments, it was not possible to determine whether treatments benefited patients during the SARS outbreak. Some may have been harmful. Clinical trials should be designed to validate a standard protocol for dosage and timing, and to accrue data in real time during future outbreaks to monitor specific adverse effects and help inform treatment.


리바비린 : 결론을 낼 수 없거나 해로울 수 있음

이뮤노글로불린 정맥 주사 : 결론을 낼 수 없음

인터페론 타입 1 : 결론을 낼 수 없음

로피나비어와 리토나비어 : 결론을 낼 수 없음

스테로이드 : 결론을 낼 수 없거나 해로울 수 있음


한약 : 치사율은 낮추지 못하나 증상 완화에는 도움이 되거나 예방의 가능성이 있음


얼마전 TV에서 의사가 메르스 치료약은 없지만 증상 완화에 도움이 되는 약은 있습니다. 그러면서 해열제, 스테로이드, 이뮤노글로불린 얘기하던데 소름 돋았다.